Episode Details

Teriflunomide (Aubagio) is approved as disease-modifying therapy for mild to moderate RRMS from 10 years of age.

You can find the full article to read on my blog: https://ms-perspektive.com/70-teriflunomide

This time it's about teriflunomide, which is known under the trade name Aubagio. The immunotherapy is used for mild to moderate courses of relapsing forms of MS.

Teriflunomide also has a broader mechanism of action and is one of the immunomodulating drugs. Please remember that I can only provide an overview here. Ask your neurologist and MS nurse for detailed advice on choosing the right therapy for you. They should know your complete state of health and be aware of your goals, wishes, fears and preferences.

"},"minimize_box":"yes","minimized_on":"tablet","hierarchical_view":"yes","min_height":{"unit":"px","size":"","sizes":[]},"min_height_tablet":{"unit":"px","size":"","sizes":[]},"min_height_mobile":{"unit":"px","size":"","sizes":[]}}" data-widget_type="table-of-contents.default"> Table of Contents

• General Information
• How is teriflunomide (Aubagio and generics) classified in immunotherapies?
• What is teriflunomide (Aubagio) approved for?
• What is the situation for special patient groups?
• Who should avoid teriflunomide?
• How does teriflunomide works?
• How is it taken?
• How effective is teriflunomide (Aubagio and generics)?
• Risks and side effects of teriflunomide (Aubagio and generics)
• Vaccinations
• Sources
• Final note

Sources

I used the following sources to create the content:

• Quality manual of the KKNMS on teriflunomide (Aubagio)
• MS-Selfie Infocards by Prof. Dr. Gavin Giovannoni
• German Multiple Sclerosis and Fertility Registry (DMSKW)
• Information from the German interview with Prof. Dr. Barbara Kornek on pediatric MS

• Listen Now